Experienced in Medium-Chain Acyl-CoA Dehydrogenase Deficiency

Guillermo M. Guerra-Diaz

Madrid, MD, ES 
Experienced in Medium-Chain Acyl-CoA Dehydrogenase Deficiency
Madrid, MD, ES 
OverviewLocationsClinical Research

Overview

Guillermo Guerra-Diaz practices in Madrid, Spain. Mr. Guerra-Diaz is rated as an Experienced expert by MediFind in the treatment of Medium-Chain Acyl-CoA Dehydrogenase Deficiency. His top areas of expertise are Osteoporosis, Hypoparathyroidism, Medium-Chain Acyl-CoA Dehydrogenase Deficiency, Liver Transplant, and Parathyroidectomy.

His clinical research consists of co-authoring 9 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Medium-Chain Acyl-CoA Dehydrogenase Deficiency.

Gender
Male

Locations

Madrid, MD, Spain

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

PARADIGHM (Physicians Advancing Disease Knowledge in Hypoparathyroidism): A Registry for Patients With Chronic Hypoparathyroidism
PARADIGHM (Physicians Advancing Disease Knowledge in Hypoparathyroidism): A Registry for Patients With Chronic Hypoparathyroidism
Enrollment Status: Active_not_recruiting
Publish Date: September 29, 2025
Intervention Type: Other
A Randomized, Double-blind, Placebo-controlled, Adaptive Study to Evaluate Symptom Improvement and Metabolic Control Among Adult Subjects With Symptomatic Hypoparathyroidism Treated With Recombinant Human Parathyroid Hormone [rhPTH(1-84)]
A Randomized, Double-blind, Placebo-controlled, Adaptive Study to Evaluate Symptom Improvement and Metabolic Control Among Adult Subjects With Symptomatic Hypoparathyroidism Treated With Recombinant Human Parathyroid Hormone [rhPTH(1-84)]
Enrollment Status: Completed
Publish Date: June 09, 2023
Intervention Type: Biological
Study Drug: rhPTH(1-84)
Study Phase: Phase 4
View 1 Less Clinical Trial

9 Total Publications

Health Outcomes in Fragility Fractures in the Spanish Registry of Osteoporotic Fractures According to the FLS Care Model.
Health Outcomes in Fragility Fractures in the Spanish Registry of Osteoporotic Fractures According to the FLS Care Model.
Journal: Archives of medical research
Published: May 26, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Guerra-Diaz's expertise for a condition
ConditionClose
      View All 7 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile